The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
Status:
Completed
Trial end date:
2020-09-14
Target enrollment:
Participant gender:
Summary
Diagnostic determination of disease and treatment responses has been limited to qualitative
imaging, measurement of serum markers of disease, and sampling of tissue. In each of these
instances, there is a built in error either due to sensitivity and specificity issues,
clinician interpretation of results, or acceptance of the use of an indirect marker (blood
test) of what is happening elsewhere in the body - at the tissue level.
The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same
state single or sequential quantification comparisons [1] provides the first and only
patented test (#9566037) - along with the associated submitted patent applications ruled to
be covered under #9566037 - that quantitatively measures changes in tissue resulting from
inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer
and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the
metabolic and regional blood flow differences (RBFDs) caused by these diseases.
The purpose of this paper is to make clinicians and researchers aware of this proposed method
for investigating the prevalence and severity of CVP - in addition to providing rapid
determination of treatment response in each patient, directing treatment decisions; thereby
reducing the loss of time, money, resources and patient lives.